Top

Japanese Journal of Ophthalmology

Published in:

01-11-2012 | Clinical Investigation

Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis

Authors: Kyoung Min Kim, Yong-Tae Shin, Hong Kyun Kim

Published in: Japanese Journal of Ophthalmology | Issue 6/2012

Abstract

Purpose

Platelet-rich plasma (PRP) harbors high concentrations of growth factors related to the promotion of wound healing. We evaluated the efficacy of PRP eyedrops in the treatment of persistent epithelial defects (PEDs).

Methods

Autologous PRP and autologous serum (AS) were prepared from whole blood. The concentrations of transforming growth factor (TGF)-β1, TGF-β2, epidermal growth factor (EGF), vitamin A and fibronectin in the PRP and AS were analyzed and compared. The corneal epithelial healing efficacy of PRP was compared with that of AS in patients with PED induced by post-infectious inflammation.

Results

The concentrations of TGF-β1, TGF-β2, EGF, vitamin A and fibronectin in the PRP and AS were not statistically different. However, the concentrations of EGF in the PRP were significantly greater than in the AS. AS was used in 17 and PRP in 11 eyes of 28 patients. The healing rates of the corneal epithelia of the PRP-treated eyes were significantly higher than those treated with AS.

Conclusions

The PRP was effective in the treatment of PEDs. This may be attributable to its high concentration of platelet-contained growth factors, most notably EGF. PRP could be an effective, novel treatment option for chronic ocular surface disease.

Watanabe K, Nakagawa S, Nishida T. Stimulatory effects of fibronectin and EGF on migration of corneal epithelial cells. Invest Ophthalmol Vis Sci. 1987;28:205–11.PubMed

Tsubota K, Xu KP, Fujihara T, Katagiri S, Takeuchi T. Decreased reflex tearing is associated with lymphocytic infiltration in lacrimal glands. J Rheumatol. 1996;23:313–20.PubMed

Tsubota K. New approaches in dry eye management. Supplying missing components to the ocular surface epithelium. Current opinions in the Kyoto Cornea Club. Amsterdam: Kugler Publications; 1997.

Barton K, Nava A, Monroy DC, Pflugfelder SC. Cytokines and tear function in ocular surface disease. Adv Exp Med Biol. 1998;438:461–9.PubMedCrossRef

Wilson SE, Linag Q, Kim WJ. Lacrimal gland HGF, KGF and EGF mRNA levels increase after corneal epithelial wounding. Invest Opthalmology Vis Sci. 1999;40:2185–90.

Panchoi S, Tullo A, Khaliq A, Foreman D, Boulton M. The effects of growth factors and conditioned media on the proliferation of human corneal epithelial cells and keratocytes. Graefes Arch Clin Exp Ophthalmol. 1998;236:1–8.CrossRef

Fukuda M, Fullard RJ, Willcox MD, Baleriola-Lucas C, Bestawros F, Sweeney D, et al. Fibronectin in the tear film. Invest Ophthalmol Vis Sci. 1996;37:459–67.PubMed

Lopez Bernal D, Ubels JL. Artificial tear composition and promotion of recovery of the damaged corneal epithelium. Cornea. 1993;12:133–8.

Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459–61.PubMedCrossRef

10.

Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106:1984–9.PubMedCrossRef

11.

Young AL, Cheng AC, Ng HK, Cheng LL, Leung GY, Lam DS. The use of autologous serum tears in persistent corneal epithelial defects. Eye. 2004;18:609–14.PubMedCrossRef

12.

Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111:1115–20.PubMedCrossRef

13.

Nishida T, Nakamura M, Ofuji K, Reid TW, Mannis MJ, Murphy CJ. Synergistic effect of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. J Cell Physiol. 1996;169:159–66.PubMedCrossRef

14.

van Setten GB, Viinikka L, Tervo T, Pesonen K, Tarkkanen A, Perheentupa J. Epidermal growth factor is a constant component of normal human tear fluid. Graefes Arch Clin Exp Ophthalmol. 1989;227:184–7.PubMedCrossRef

15.

Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res. 1996;14:605–14.CrossRef

16.

Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet derived wound healing formula. Surg Gynecol Obstet. 1990;170:56–9.PubMed

17.

Esnesto C. Growth factors and their potential clinic value. J Clin Endocrinol Metab. 1992;170:56–69.

18.

Lynch SE, Colvin RB, Antoniades HN. Growth factors in wound healing: single and synergistic effects in partial thickness porcine skin wounds. J Clin Invest. 1989;84:640–6.PubMedCrossRef

19.

Alio JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J. Use of autologous platelet rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007;114:1286–93.PubMedCrossRef

20.

Alio JL, Pastor S, Ruiz-Colecha J, Rodriguez A, Artola A. Treatment of ocular surface syndrome after LASIK with autologous platelet rich plasma. J Refract Surg. 2007;23:617–9.PubMed

21.

Katsui G. Assay methods of vitamin A. Assay methods of vitamin A in blood and tissues (in Japanese). Vitamins. 1982;56:97–101.

22.

Scardovi C, De Felice GP, Gazzaniga A. Epidermal growth factor in the topical treatment of traumatic corneal ulcers. Ophthalmology. 1993;206:119–24.CrossRef

23.

Pastor JC, Calonge M. Epidermal growth factor and corneal wound healing: a multicenter study. Cornea. 1992;11:311–4.PubMedCrossRef

24.

Collins MK, Perkins GR, Rodriguez-Tarduchy G, Nieto MA, López-Rivas A. Growth factors as survival factors: regulation of apoptosis. Bioessays. 1994;16:133–8.PubMedCrossRef

25.

Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci. 1997;110:113–21.PubMed

26.

Haber M, Cao Z, Panjwani N, Bedenice D, Li WW, Provost PJ. Effects of growth factors (EGF, PDGF-BB and TGF beta 1) on cultured equine epithelial cells and keratocytes: implications for wound healing. Vet Ophthalmol. 2003;6:211–7.PubMedCrossRef

27.

Vesaluoma M, Teppo AM, Gronhagen-Riska C, Tervo T. Release of TGF-beta 1 and VEGF in tears following photorefractive keratectomy. Curr Eye Res. 1997;16:19–25.PubMedCrossRef

28.

Spigelman AV, Deutsch TA, Sugar J. Application of homologous fibronectin to persistent human corneal epithelial defects. Cornea. 1987;6:128–30.PubMedCrossRef

29.

Nishida T, Nakagawa S, Awata T, Ohashi Y, Watanabe K, Manabe R. Fibronectin promotes epithelial migration of cultured rabbit cornea in situ. J Cell Biol. 1983;97:1653–7.PubMedCrossRef

30.

Nishida T, Nakagawa S, Awata T, Nishibayashi C, Manabe R. Rapid preparation of purified autologous fibronectin eyedrops from patient’s plasma. Jpn J Ophthalmol. 1982;26:416–24.PubMed

31.

Nishida T, Ohashi Y, Awata T, Manabe R. Fibronectin. A new therapy for corneal trophic ulcer. Arch Ophthalmol. 1983;101:1046–8.PubMedCrossRef

32.

Pfister RR, Renner ME. The corneal and conjunctival surface in vitamin A deficiency: a scanning electron microscopy study. Invest Ophthalmol Vis Sci. 1978;17:874–83.PubMed

33.

Sommer A. Xerophthalmia and vitamin A status. Prog Retin Eye Res. 1998;17:9–31.PubMedCrossRef

34.

Ubels JL, Iorfino A, O’Brien WJ. Retinoic acid decreases the number of EGF receptors in corneal epithelium and Chang conjunctival cells. Exp Eye Res. 1991;52:763–5.PubMedCrossRef

35.

Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001;20:807–10.PubMedCrossRef

36.

del Castillo JM, de la Casa JM, Sardiña RC, Fernández RM, Feijoo JG, Gómez AC, et al. Treatment of recurrent corneal erosions using autologous serum. Cornea. 2002;21:781–3.PubMedCrossRef

37.

Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, et al. Treatment of dry eye by autologous serum application in Sjögren’s syndrome. Br J Ophthalmol. 1999;83:390–5.PubMedCrossRef

38.

Poon AC, Geerling G, Dart JK, Fraenkel G, Daniels J. Autologous serum eyedrops for dry eye and epithelial defect: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85:1188–97.PubMedCrossRef

39.

Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802–6.PubMedCrossRef

40.

Noble BA, Loh RSK, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, et al. Comparison of autologous serum eyedrops with conventional therapy in a randomized controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004;88:647–52.PubMedCrossRef

41.

Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4–15.PubMed

42.

Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr Med Chem. 2004;11:2245–60.PubMedCrossRef

43.

Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res. 2002;22:913–22.PubMedCrossRef

44.

Boehlen F, Clemetson KJ. Platelet chemokines and their fusion practice? Transfus Med. 2001;11:403–17.PubMedCrossRef

45.

Englert SJ, Estep TH, Ellis-Stoll CC. Autologous platelet gel applications during cardiovascular surgery: effect on wound healing. J Extra Corpor Technol. 2005;37:148–52.PubMed

46.

Sammartino G, Tia M, Marenzi G, di Lauro AE, D’Agostino E, Claudio PP. Use of autologous platelet-rich plasma in periodontal defect treatment after extraction of impacted mandibular third molars. J Oral Maxillofac Surg. 2006;63:766–70.CrossRef

47.

Choi BH, Im CJ, Huh JY, Suh JJ, Lee SH. Effect of platelet-rich plasma on bone regeneration in autologous bone graft. Int J Oral Maxillofac Surg. 2004;33:56–9.PubMedCrossRef

48.

Marx RE. Platelet rich plasma: what is platelet-rich plasma and what is not platelet-rich plasma? Implant Dent. 2001;10:225–8.PubMedCrossRef

49.

Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg. 2001;107:229–37.PubMedCrossRef

50.

Bhanot S, Alex JC. Current applications of platelet gels in facial plastic surgery. Facial Plast Surg. 2002;18:27–33.PubMedCrossRef

51.

Hartwig D, Harloff S, Liu L, Schlenke P, Wedel T, Geerling G. Epitheliotrophic capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial cells: a potential agent for the treatment of ocular surface defects? Transfusion. 2004;44:1724–31.PubMedCrossRef

52.

Gospodarowicz D, Bialecki H, Thakral TK. The angiogenic activity of the fibroblast and epidermal growth factor. Exp Eye Res. 1979;28:501–14.PubMedCrossRef

Title: Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis
Authors: Kyoung Min Kim
Yong-Tae Shin
Hong Kyun Kim
Publication date: 01-11-2012
Publisher: Springer Japan
Published in: Japanese Journal of Ophthalmology / Issue 6/2012
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI: https://doi.org/10.1007/s10384-012-0175-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2012

Macular thickness measured by spectral-domain optical coherence tomography in healthy Thai eyes

Scientific Reviewers

Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy

Serial measurements of accommodation by open-field Hartmann–Shack wavefront aberrometer in eyes with accommodative spasm

Hong’s grading for evaluating anterior chamber angle width

One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation